JUNSHI BIO (688180.SH): Application for clinical trials of injectable JS212 has been accepted.

08/01/2025

GMT Eight

JUNSHI BIO (688180.SH) announces that the company has received the "Acceptance Notification" issued by the National Medical Products Administration for the clinical trial application of injection JS212 (project code "JS212"). JS212 is a recombinant humanized dual-specific antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), primarily used for the treatment of advanced malignant solid tumors.

MOBI DEV (00947) repurchased 32,000 shares on January 8th.

ANTA SPORTS(02020): In the fourth quarter, the retail sales of ANTA brand products achieved a high single-digit year-on-year growth.

Contact: contact@gmteight.com

JUNSHI BIO (688180.SH): Application for clinical trials of injectable JS212 has been accepted.

RECOMMEND

Shunfa Hengneng Corporation (000631.SZ) plans to spend 250 million to 500 million yuan to repurchase shares.

GLOBAL SWEET (03889) has completed the issuance of a total of 41 million subscribed shares.

C.Q. Pharmaceutical Holding (000950.SZ) issued a profit warning, with an estimated net profit of 290 million to 390 million yuan, a year-on-year decrease of 40.45% to 55.72%.